Whitehawk Therapeutics Inc Price & Performance (WHWK)

Kaken Pharmaceutical has completed its acquisition of Aadi Subsidiary, Inc. from Whitehawk Therapeutics for $102.4 million, including the FYARRO business and trademarks. The deal, approved by Aadi shareholders, boosts Whitehawk’s liquidity, supporting its focus on antibody drug conjugate development and extending its operational runway into late 2028.12

Aadi Bioscience’s stock slipped 0.6% in trading, but institutional investors continue to hold over 50% of shares, signaling long-term confidence. Despite negative earnings, Aadi outperforms peers like Biomerica in several key metrics, including revenue and insider ownership, according to recent comparative analysis.34

Whitehawk Therapeutics has closed the sale of its Aadi Subsidiary to Kaken for $100 million, marking a strategic pivot to its antibody drug conjugate (ADC) program. The cash infusion, combined with recent financing, is expected to fund operations and clinical milestones through 2028, despite ongoing cash burn concerns.56